Regulatory Affairs Syndicator

Hyperion Therapeutics, Inc. announced that its investigational product HPN-100 has received orphan product designation from the U.S. Food and Drug Administration for intermittent or chronic treatment of patients with cirrhosis and any grade of hepatic encephalopathy.